Not a good buy right now: trend is technically bearish (SMA_200 > SMA_20 > SMA_5) and price is pressing into near-term resistance around 17.24–17.68.
Options positioning is skewed bearish/defensive (high put open-interest vs calls), and there’s no supportive proprietary buy signal today.
Fundamentals recently deteriorated (2025/Q3 revenue down YoY, negative EPS, sharp gross-margin compression), which weakens the case for an impatient entry.
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), implying the broader trend remains down.
Momentum: MACD histogram is negative (-0.0953) but contracting, suggesting downside momentum is easing (not yet a confirmed reversal).
RSI: RSI_6 at 62.21 is neutral-to-slightly warm, but not strong enough to override bearish MA structure.
Levels: Pivot 16.534; Support S1 15.823 (then 15.384). Resistance R1 17.244 (price ~17.25 is right at it) and R2 17.683—risk of rejection is elevated when buying directly into resistance.
Pattern-based forward bias: Similar-pattern stats imply weak next-day expectation (-0.28%) but stronger 1-week (+4.97%) and 1-month (+11.24%) drift; however, current positioning near resistance makes the immediate entry less attractive.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment (open interest): Put OI 1369 vs Call OI 470; OI put/call 2.91 signals bearish or heavy hedging bias.
Activity/liquidity: Very low options volume (todays_volume 3; calls volume 0), so the day’s volume-based put/call (0.0) is not very informative.
Volatility: IV 30d 45.79 vs historical vol 61.38 (IV looks discounted vs realized); IV rank 13.42 and IV percentile 32.4 suggest options are not pricing extreme fear.
Technical Summary
Sell
5
Buy
9
Positive Catalysts
and reclaim/hold above R1–R
Neutral hedge fund/insider trend data suggests no active distribution signal from these cohorts in the provided window.
Neutral/Negative Catalysts
and ~17.68 (R2); price is currently right at R1, increasing the odds of a fade.
reflects cautious-to-bearish positioning.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 374.473M, down -5.96% YoY (contraction).
Profitability: Net income -2.638M (down -111.85% YoY), indicating a swing into loss.
EPS: -0.10, down -112.20% YoY.
Gross margin: 6.78%, down -52.88% YoY (major margin compression and the biggest fundamental red flag in the snapshot).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so recent Wall Street revisions cannot be verified from the dataset.
Wall Street-style pros (based on provided data): potential mean reversion if momentum continues improving into earnings.
Wall Street-style cons (based on provided data): deteriorating 2025/Q3 profitability and sharply lower gross margin, plus bearish technical trend and defensive options open-interest skew.
Politicians/influential figures: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast ASIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASIX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast ASIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASIX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 17.840
Low
0
Averages
0
High
0
0
Current: 17.840
Low
0
Averages
0
High
0
Piper Sandler
Piper Sandler
Neutral
to
Overweight
upgrade
$26 -> $32
AI Analysis
2025-05-19
Reason
Piper Sandler
Piper Sandler
Price Target
$26 -> $32
AI Analysis
2025-05-19
upgrade
Neutral
to
Overweight
Reason
Piper Sandler last night upgraded AdvanSix to Overweight from Neutral with a price target of $32, up from $26. The firm cites the earnings benefit of the ammonium sulfate business as well as the relatively small impact of tariffs and the nylon, nylon intermediate and chemical intermediate businesses for the upgrade. Piper sees AdvanSix's earnings holding up better than most other chemical shares. AdvanSix's EBITDA is "far from a peak level," making the shares "significantly undervalued," Piper contends.
Piper Sandler
Neutral -> Overweight
upgrade
$26 -> $32
2025-05-18
Reason
Piper Sandler
Price Target
$26 -> $32
2025-05-18
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded AdvanSix to Overweight from Neutral with a price target of $32, up from $26.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ASIX